We perform large genome and gene expression analyses of patient samples and patient-derived cell cultures and correlate these results with clinical observations identifying genes and processes that can be used clinically for improved, more precise treatment and diagnosis. Identified processes and gene variants are followed up to better understand the mechanisms underlying the observed difference. All studies are performed in close collaboration with the other units within CAG-IBD, as well as the clinic.

Objectives for ongoing research activities:

1. Identify genetic variants that predispose for a complicated disease course and poor treatment outcome in IBD.
2. Characterize the mechanisms underlying the effect of these genetic variants, for example through sequence variants in miRNA binding sites.
3. Evaluate if the identified genetic variants are efficient and reproducible biomarkers for use in the clinic.
4. Elucidate epithelial involvement in regulating the intestinal inflammation seen in IBD through gene expression analyses of epithelial cells from IBD patients and experiments in patient-derived epithelial cell lines.
5. Characterize the role of serotonin and epithelial serotonin reuptake transporter in intestinal fibrosis.
6. Investigate how epithelial regeneration is balanced in an inflamed intestinal environment.